Comparative evaluation of oncolytic viruses reveals opposing preferences for glioblastoma subtypes. [PDF]
Deconinck T +4 more
europepmc +1 more source
Cracking the shield: oncolytic viruses versus the tumor-immune fortress. [PDF]
El-Derby AM +3 more
europepmc +1 more source
Oncolytic Viruses as In Situ Cancer Vaccines: Tumor Microenvironment Remodeling, Checkpoint Inhibitor Synergy, and Biomarker-Guided Clinical Translation. [PDF]
Rogalski K +8 more
europepmc +1 more source
Chemokine-Armed Oncolytic Viruses: Engineering Immune Cell Trafficking to Transform the Tumor Microenvironment. [PDF]
Alwithenani A.
europepmc +1 more source
Oncolytic viruses in lung cancer: mechanisms of action and research progress. [PDF]
Ji T +6 more
europepmc +1 more source
Oncolytic viruses: advanced strategies in cancer therapy. [PDF]
Xiao D +5 more
europepmc +1 more source
Engineering megakaryocytes with oncolytic viruses for <i>in situ</i> generation of therapeutic platelets. [PDF]
Yang Y, Gu Z, Yu J.
europepmc +1 more source
The interplay between oncolytic viruses, Toll-like receptor signaling, and chemotherapy in overcoming tumor immune tolerance. [PDF]
Wu YY +5 more
europepmc +1 more source
In silico clinical trials of BiTE expression by oncolytic viruses reveal the impact of patient heterogeneity on dosage protocol. [PDF]
Jenner AL +5 more
europepmc +1 more source
Overcoming melanoma drug resistance: Mechanisms and clinical progress of oncolytic viruses combined with immune checkpoint inhibitors (Review). [PDF]
He Y +6 more
europepmc +1 more source

